LP
TMO icon

Longview Partners’s Thermo Fisher Scientific TMO Stock Holding History

Longview Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326M Sell
662,828
-187,448
-22% -$102M 4.62% 2
2025
Q4 		$493M Sell
850,276
-53,290
-6% -$30.1M 5.15% 4
2025
Q3 		$438M Buy
903,566
+34,981
+4% +$16.3M 4.58% 9
2025
Q2 		$352M Sell
868,585
-45,600
-5% -$19.1M 3.03% 22
2025
Q1 		$455M Sell
914,185
-56,619
-6% -$30.7M 3.66% 18
2024
Q4 		$505M Sell
970,804
-41,263
-4% -$22.7M 3.77% 16
2024
Q3 		$626M Buy
1,012,067
+8,338
+0.8% +$4.94M 4.29% 11
2024
Q2 		$555M Sell
1,003,729
-135,390
-12% -$77.6M 4.12% 14
2024
Q1 		$662M Sell
1,139,119
-32,590
-3% -$18.3M 4.28% 10
2023
Q4 		$622M Buy
+1,171,709
New +$567M 4.15% 11
2019
Q1 		– Sell
-1,484,698
Closed -$332M – 27
2018
Q4 		$332M Sell
1,484,698
-28,365
-2% -$6.66M 1.77% 23
2018
Q3 		$369M Sell
1,513,063
-1,706,592
-53% -$393M 1.82% 22
2018
Q2 		$667M Sell
3,219,655
-190,875
-6% -$40.5M 3.47% 17
2018
Q1 		$704M Sell
3,410,530
-1,466,360
-30% -$308M 3.69% 17
2017
Q4 		$926M Buy
4,876,890
+311,977
+7% +$59.8M 4.85% 16
2017
Q3 		$864M Buy
4,564,913
+313,782
+7% +$56.8M 4.67% 17
2017
Q2 		$742M Buy
4,251,131
+84,180
+2% +$14.1M 4.28% 14
2017
Q1 		$640M Sell
4,166,951
-200,575
-5% -$30.7M 4.16% 16
2016
Q4 		$616M Sell
4,367,526
-186,213
-4% -$27.5M 4.07% 18
2016
Q3 		$724M Sell
4,553,739
-376,823
-8% -$58.1M 4.69% 6
2016
Q2 		$729M Sell
4,930,562
-125,708
-2% -$18.6M 4.85% 5
2016
Q1 		$716M Sell
5,056,270
-123,096
-2% -$16.5M 4.76% 6
2015
Q4 		$735M Buy
5,179,366
+54,191
+1% +$7.23M 5.01% 2
2015
Q3 		$627M Buy
+5,125,175
New +$668M 4.43% 13

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Longview Partners's TMO Position: Q1 2026 in Review

Longview Partners reduced its Thermo Fisher Scientific (TMO) stake by 22% in Q1 2026, selling an estimated $102M and leaving 662,828 shares worth $326M. The position accounts for 4.62% of the portfolio, ranked #2.

Longview Partners first reported a position in TMO in Q3 2015 and has held it in 24 quarters since. The position peaked at $926M in Q4 2017. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Longview Partners held 662,828 shares of Thermo Fisher Scientific worth $326M as of Q1 2026.
  • Longview Partners sold 187,448 Thermo Fisher Scientific shares in Q1 2026, an estimated $102M.
  • Thermo Fisher Scientific made up 4.62% of Longview Partners's portfolio in Q1 2026, its #2 holding.
  • Longview Partners first reported a position in Thermo Fisher Scientific in Q3 2015 and has held it in 24 quarters since.
  • Longview Partners's Thermo Fisher Scientific position peaked at $926M in Q4 2017.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Longview Partners's 13F filing for Q1 2026, filed 15 May 2026.